Ferring Pharmaceuticals: Ferring Presents New Subgroup Analy

Subgroup analysis of Phase 3 trial (PUNCH CD3) looked at health-related quality of life data in patients treated with RBX2660 versus placebo Separate subgroup analysis reviewed efficacy and

Related Keywords

Switzerland , United States , America , Kostenloser Wertpapierhandel , Paul Feuerstadt , Lisa Ellen , Instagram , Medicine Association , Us Centers For Disease , Linkedin , Society For Healthcare Epidemiology Of America , Twitter , Yale University School Of Medicine , Facebook , Centers For Disease , Brand Communications , Significant Improvement In Health , Drug Administration , Ferring Pharmaceuticals , Pediatric Infectious Diseases Society , Youtube , Society Of Infectious Diseases Pharmacists , Infectious Diseases Society Of America , Infectious Disease Week , Significant Improvement , Health Related Quality , Placebo Controlled Trial , Recurrent Clostridioides Difficile Infection , Life Questionnaire , Yale University School , Recurrent Clostridioides , Underlying Comorbidities , Disease Control , Breakthrough Therapy , Infectious Diseases Society , Healthcare Epidemiology , Infectious Diseases Pharmacists , Biggest Threats , Dis Clin North , Manag Care Spec Pharm , Clin Microbiol , Rev Dis , Spreferring , Pharmaceuticals , Presents , Subgroup , Analyses , Health , Elated , Quality , Life , Safety , Efficacy , Data , Midweek , 022 , Bx2660 , Investigational , Microbiota , Ased , Five , Biotherapeutic ,